Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
British Journal of Clinical Pharmacology
|
December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
Melanoma Research
|
June 21, 2019
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status
Amanda Truong, John R Hyngstrom, Robert H I Andtbacka, et al.
Cancer Immunology, Immunotherapy : CII
|
June 10, 2016
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
David D Stenehjem, Michael Toole, Joseph Merriman, et al.
Cell
|
September 21, 2010
DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC
Kunal Rai, Sharmistha Sarkar, Talmage J Broadbent, et al.
Oncotarget
|
July 9, 2016
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray, Matthew A Williams, Stephanie M Meek, et al.
Cancer
|
September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Journal for Immunotherapy of Cancer
|
June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
The Lancet. Oncology
|
September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
British Journal of Clinical Pharmacology
|
December 16, 2017
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R Infante, et al.
Melanoma Research
|
June 21, 2019
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status
Amanda Truong, John R Hyngstrom, Robert H I Andtbacka, et al.
Cancer Immunology, Immunotherapy : CII
|
June 10, 2016
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2
David D Stenehjem, Michael Toole, Joseph Merriman, et al.
Cell
|
September 21, 2010
DNA demethylase activity maintains intestinal cells in an undifferentiated state following loss of APC
Kunal Rai, Sharmistha Sarkar, Talmage J Broadbent, et al.
Oncotarget
|
July 9, 2016
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray, Matthew A Williams, Stephanie M Meek, et al.
Cancer
|
September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Journal of Clinical Pharmacology
|
December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib
A Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Journal for Immunotherapy of Cancer
|
June 12, 2021
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia, Robert R McWilliams, Olivier Rixe, et al.
Nature Medicine
|
October 6, 2020
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain P Algazi, Megan Othus, Adil I Daud, et al.
The Lancet. Oncology
|
September 14, 2016
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F Stephen Hodi, Jason Chesney, Anna C Pavlick, et al.
Page
of 4